We are celebrating Shanti Swarup Bhatnagar Award (one of the highest multidisciplinary science awards in India) and recent achievements of Prof. Rohit Srivastava. Therefore, to recognize Prof. Rohit’s contribution in translational research, a special issue will be published by Nanotheranostics.
This thematic issue would be on Translational Nanomedicines and Biosensors. Prof Rohit Srivastava, a Himanshu Patel Chair Professor at the Department of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, has recently received the Shanti Swarup Bhatnagar Prize and contributed in translational research significantly. He is one of the pioneering scientists in the area of translational research. About 150 researchers were trained in Prof. Rohit’s lab at various levels (Master, Ph.D., Postdocs). Currently, his lab comprises about 60 researchers who are developing cutting edge technologies. He has contributed to more than 300 publications, including research papers, review articles, books, and book chapters. Prof Rohit Srivastava has been granted a total of 30 patents (including 3 U.S. patents and 27 Indian patents) and currently has over 150+ IDFs, Trademarks, Design Registrations, and patents filed or in the process of being filed.
Translational nanomedicine is an interdisciplinary field that combines nanotechnology, medicine, and biology to improve medical interventions and patient outcomes. Within the field, scientists utilize nanotechnology-based approaches, such as nanoparticles, nanocarriers, or nanodevices, and adapt them for use in diagnosing, treating, and preventing diseases. Nanomaterials can be engineered to carry therapeutic agents, such as drugs, genes, or proteins, to specific sites within the body. They can be designed to improve drug solubility, enhance drug stability, and protect therapeutic agents from degradation until they reach their target. Furthermore, they can be surface-functionalized with ligands or antibodies that specifically recognize and bind to receptors on target cells, enabling precise drug delivery. Despite its tremendous promise, substantial challenges impede the full clinical utilization of nanomedicine. These challenges include manufacturing scalability, long-term toxicological concerns, regulatory considerations, off-targets effects produced from poor biodistribution, and nanomaterial immunogenicity. Overcoming these limitations will require sustained research efforts, close interaction between academia, industry, and regulatory bodies, and the adoption of rigorous safety evaluations and standards.
The proposed special issue aims to provide a platform for researchers, scientists, clinicians, and engineers to share their latest findings, methodologies, and perspectives on translational nanomedicine. We anticipate that this collection of papers will showcase cutting-edge research, highlight technological advancements, and address critical challenges in the field. The special edition will serve as a comprehensive resource for both experts and newcomers, fostering collaboration and driving further innovation.
Relevant topics include (but are not limited to):
Manuscripts for the special issue can be submitted online at https://www.ntno.org/ms/submit (mark “Translational Nanomedicines and Biosensors: Special Issue" in the "Suggested reviewers" field to identify the paper) between July, 15, 2023 to June, 15, 2024.
Detailed formatting instructions, in particular, the formatting of references, can be found in https://www.ntno.org/ms/author.
All inquiries should be sent to the guest editor at the above email address.